Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma founder to chair Glide Pharma

Bryan Morton replaces Mark Kirby

Glide-Pharma-Bryan-MortonGlide Pharma has appointed Bryan Morton as its new non-executive chairman.

Morton replaces Mark Kirby at the UK-based company, which focuses on developing treatments that use its solid dose injector platform for administration.

Morton was most recently chief executive at oncology specialist EUSA Pharma – a company he also founded. EUSA was sold to Jazz Pharmaceuticals in 2012 for $700m.

His other entrepreneurial experience in the industry includes founding Zeneus Pharma, which was acquired by Cephalon for $360m.

Other previous positions held by Morton include president of Convatec EMEA, as well as a string of senior roles during a 20-year career at Merck & Co.

“His significant experience of building successful pharmaceutical companies will prove invaluable as Glide begins its next stage of development,” said Kirby on the appointment of his successor.

Commenting on the future of Glide Pharma under his direction Morton said: "Having completed a significant investment round earlier this year and winning a large funding award from the UK Biomedical Catalyst, the company is well positioned, and I look forward to helping the team exploit the value of Glide's unique technology.”

In addition to the appointment of Morton, Glide also announced that Dr Charles Potter is to step down from the board and his role as the company's chief business officer.

10th October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics